Precirix

Precirix is a clinical-stage biotechnology company based in Brussels, Belgium, founded in 2014.

The company specializes in developing precision radiopharmaceuticals for cancer treatment, utilizing camelid single-domain antibodies (sdAbs) labeled with radioisotopes. Precirix focuses on oncology and targeted radionuclide therapy, aiming to provide personalized treatment options for cancer patients. The company has a diverse pipeline, including its lead product, CAM-H2, which is currently in a Phase I/II clinical trial targeting HER2-positive metastatic cancer. Precirix is also advancing programs targeting Fibroblast Activation Protein (FAP), which has the potential to be a first-in-class alpha-emitting therapy. Their theranostic approach combines imaging for patient selection with targeted alpha-emitting radiation, enhancing treatment precision and efficacy. With a dedicated team of approximately 22–35 employees, Precirix has successfully raised over $129 million in funding from various investors, positioning itself as a key player in the biotechnology industry focused on innovative cancer therapies.